RxDoctor Payments Data

Stephen Harkins, DDS

Oral and Maxillofacial Surgery · Tucson, AZNPI 1477599827

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 31.9% of the total. Reporting peaked in 2023 at $491 and has fallen 63.5% since, to $179 in 2025.

$1,820in general payments, 2019–2025

Across 63 payments — averaging $28.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$580
  • Novartis$215
  • Teva Pharmaceuticals USA, Inc.$201
  • Pfizer$160
  • Biohaven Pharmaceuticals, Inc.$158
  • Watermark Medical, Inc.$101
  • plus $406 from 9 others

What the payments were for

  • Food & beverage$1,820100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,820 in reported general payments places this provider in the 60th percentile of 147 oral and maxillofacial surgery providers in Arizona.

See all oral and maxillofacial surgery providers in Arizona

Medicare billing

Part B allowed, 2024
$132,333
Medicare patients
281
Services billed
1,871

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Baclofen52$723
Doxepin Hcl30$636
Tizanidine Hcl51$568

Paid to pharmacies, not to this prescriber.

Other oral and maxillofacial surgery in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →